Get started
Author

Nobuyuki Yasuda

Observed names: N Yasuda, N. Yasuda
ORCID: 0000-0003-0117-0784
Observed ORCID: 0000-0003-0117-0784
OpenAlex ID: A5061087608
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
2002 · Nobuyuki Yasuda, Takashi Inoue, et al. · Biochemical and Biophysical Research Communications · 137
2-Alkynyl-8-aryl-9-methyladenines as Novel Adenosine Receptor Antagonists: Their Synthesis and Structure−Activity Relationships toward Hepatic Glucose Production Induced via Agonism of the A2BReceptor
2000 · Hitoshi Harada, Osamu Asano, et al. · Journal of Medicinal Chemistry · 113
Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats
2001 · Tadashi Nagakura, Nobuyuki Yasuda, et al. · Biochemical and Biophysical Research Communications · 95
Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes
2003 · Nobuyuki Yasuda, Takashi Inoue, et al. · European Journal of Pharmacology · 68
Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats
2004 · Nobuyuki Yasuda, Takashi Inoue, et al. · Journal of Pharmacology and Experimental Therapeutics · 63
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis
2017 · Yoshiya Tanaka, Tsutomu Takeuchi, et al. · Modern Rheumatology · 61
Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
2016 · Toshio Imai, Nobuyuki Yasuda · Inflammation and Regeneration · 61
PDF
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
2003 · Tadashi Nagakura, Nobuyuki Yasuda, et al. · Metabolism · 55
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats
2002 · Nobuyuki Yasuda, Tadashi Nagakura, et al. · Life Sciences · 52
Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes
2003 · Hironobu Hiyoshi, Mamoru Yanagimachi, et al. · Journal of Lipid Research · 47
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases
2020 · Yoshiya Tanaka, Kana Hoshino-Negishi, et al. · ImmunoTargets and Therapy · 41
PDF
Role of Anti‐Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis
2018 · Kana Hoshino‐Negishi, Masayoshi Ohkuro, et al. · Arthritis & Rheumatology · 34
Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
2020 · Yoshiya Tanaka, Tsutomu Takeuchi, et al. · Arthritis & Rheumatology · 32
PDF
2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure–activity relationships of effects on hepatic glucose production induced via agonism of the A2B adenosine receptor
2001 · Hitoshi Harada, Osamu Asano, et al. · Bioorganic & Medicinal Chemistry · 31
The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight
2004 · Kazuto Yamazaki, Nobuyuki Yasuda, et al. · European Journal of Pharmacology · 28
Blockade of the fractalkine–CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes
2019 · Yoshikazu Kuboi, Miyuki Nishimura, et al. · International Immunology · 27
Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice
2007 · Kazuto Yamazaki, Takashi Inoue, et al. · Journal of Pharmacological Sciences · 27
PDF
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs
2021 · Yoshiya Tanaka, Tsutomu Takeuchi, et al. · Modern Rheumatology · 25
Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study
2018 · Hiroko Tabuchi, Toshinori Katsurabara, et al. · The Journal of Clinical Pharmacology · 24
Blockade of the fractalkine–CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes
2019 · Yoshikazu Kuboi, Miyuki Nishimura, et al. · International Immunology · 20
PDF
E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor
2006 · Nobuyuki Yasuda, Tadashi Nagakura, et al. · European Journal of Pharmacology · 18
Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats
2006 · Kazuto Yamazaki, Nobuyuki Yasuda, et al. · Journal of Pharmacology and Experimental Therapeutics · 16
7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one Is a Novel Competitive and Selective Inhibitor of Dipeptidyl Peptidase IV with an Antihyperglycemic Activity
2006 · Kazuto Yamazaki, Nobuyuki Yasuda, et al. · Journal of Pharmacology and Experimental Therapeutics · 16
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate
2023 · Yoshiya Tanaka, Tsutomu Takeuchi, et al. · Modern Rheumatology · 10
The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival
2022 · Yoshikazu Kuboi, Yukiko Kuroda, et al. · JBMR Plus · 9
PDF
Works count: 42
Citation count: 1,137
H-index: 20
I10-index: 24
Year
Topic
Type